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Acute lymphoblastic leukemia (ALL) is a frequent neoplasia occurring in children. The
most commonly used drug for the treatment of ALL is methotrexate (MTX), an anti-folate
agent. Previous studies suggest that folate transporters play a role in ALL prognosis and
that genetic polymorphism of genes encoding folate transporters may increase the risk
of ALL. Therefore, the main goal of this study was to determine the associations among
six genetic polymorphisms in four genes related with the folate transporter pathway to
determine a relationship with the occurrence of ALL in Mexican children. A case-control
study was performed in 73 ALL children and 133 healthy children from Northern
and Northwestern Mexico. COL18A1 (rs2274808), SLC19A1 (rs2838956), ABCB1
(rs1045642 and rs1128503), and ABCC5 (rs9838667 and rs3792585). Polymorphisms
were assayed through qPCR. Our results showed an increased ALL risk in children
carrying CT genotype (OR = 2.55, CI 95% 1.11–5.83, p = 0.0001) and TT
genotype (OR = 21.05, CI 95% 5.62–78.87, p < 0.0001) of COL18A1 rs2274808; in
SLC19A1 rs2838956 AG carriers (OR = 44.69, CI 95% 10.42–191.63, p = 0.0001);
in ABCB1 rs1045642 TT carriers (OR = 13.76, CI 95% 5.94–31.88, p = 0.0001);
in ABCC5 rs9838667 AC carriers (OR = 2.61, CI 95% 1.05–6.48, p < 0.05); and in
ABCC5 rs3792585 CC carriers (OR = 9.99, CI 95% 3.19–31.28, p = 0.004). Moreover,
several combinations of genetic polymorphisms were found to be significantly associated
with a risk for ALL. Finally, two combinations of ABCC5 polymorphisms resulted in
protection from this neoplasia. In conclusion, certain genetic polymorphisms related to
the folate transport pathway, particularly COL18A1 rs2274808, SLC19A1 rs2838956,
ABCB1 rs1045642, and ABCC5 rs3792585, were associated with an increased risk for
ALL in Mexican children.
Keywords: acute lymphoblastic leukemia, folate transporters, genetic polymorphisms, methotrexate, molecular
epidemiology
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a malignant cancer
disorder with an etiology not yet completely understood (Zeller
et al., 2005). Its prevalence of ∼34 to 35:100,000 in the Mexican
pediatric population, accounting for 80–85% of all childhood
leukemia found in northwestern Mexico (Rodríguez et al., 2010).
Many factors, such as, physical, chemical, and genetic causes, are
associated with ALL susceptibility in pediatric patients (Skibola
et al., 1999).
The choice of chemotherapy treatment for ALL is based
on the St. Jude Total XV protocol with antifolate drugs, as
methotrexate (MTX; Pui et al., 2009, 2010). Three cellular
mechanisms for folate transport have been identified: folate
receptors (FR), reduced folate carrier (RFC), and the newly
described proton-coupled folate transporter (PCFT). RFC 1
(reduced folate carrier 1), a 57–65 kDa integral transmembrane
and energy-dependent protein, also called SLC19A1, member of
the SLC19 family of solute carriers belonging to the ABC (ATP-
binding cassette transporter family; Takatori et al., 2006) is the
primarily way for folate or antifolate drugs transport (Sirotnak
and Tolner, 1999; Ganapathy et al., 2004).
RFC1 is encoded by RFC1 (SLC19A1) gene located at
chromosome 21 (locus 21q22.2-q22.3;Moscow et al., 1997; Jansen
and Pieters, 1998). Moscow et al. demonstrated that RFC1 is
over-expressed in cancer cell lines, mainly in breast cancer and
leukemia. This over-expression produces an increased in vitro
cytotoxicity due to contact with MTX, which may explain the
affinity of these receptors to the anti-folates (Moscow et al.,
1997). RFC1 transport function is enhanced by another protein,
Collagen alpha-1 (XVIII) chain, encoded by COL18A1 (locus
21q22.3), and has been described as crucial for malignant
processes due to endostatin production (Digtyar et al., 2007),
which is a powerful angiogenesis and tumor growth inhibitor
(Sertie et al., 2000).
Conversely, MDR1 and MRP5, belonging to an important
eﬄux transporter protein family of drugs and their metabolites
called multidrug resistance proteins (MDR and/or MRP),
have been shown to be important in the treatment of cancer
cells (Higgins, 2001; Holland and Holland, 2005). These
proteins are encoded by highly polymorphic genes (ABCB1
and ABCC5) that have been associated with increased ALL
risk and have also been implicated in oncologic treatment
interpatient variability (Gottesman et al., 2002; Brisson
et al., 2015), specifically against anti-folate drugs (Wielinga
et al., 2005), leading to an increased risk of relapse (Choi,
2005). There is evidence that MRP5 transporter is over-
expressed in the biological barriers of the brain, which could
support the idea that ALL patients frequently relapse in the
central nervous system (Warren et al., 2009); therefore, some
genotypic modifications in the gene ABCC5 would enhance
the severity of ALL. Disruptions of the homeostasis of the
one-carbon metabolism are attributed to folate deficiencies,
leading to DNA damage. Therefore, genetic defects and
polymorphisms in these pathways may have influence in cancer
susceptibility and therapeutic response (Homberger et al.,
2000).
Therefore, in this research we aimed to evaluate the influence
of six genetic polymorphisms in these membrane folate transport
associated-proteins on the ALL susceptibility development, to
expand the understanding of these variants as potential genetic
risk factors for ALL pathogenesis.
MATERIALS AND METHODS
General Study Design
This research was performed as an observational prospective,
case-control, association study. This study was approved on April
17th, 2013 by the CECAN Ethics and Research Committee,
Durango, Mexico, in accordance with the Helsinki Declaration,
Good Clinical Practices (CGP), and Mexican General Health
Law. Signed informed assent and consent were obtained from
all children, and patients and controls were tutored before
participation in the study.
Seventy-three pediatric ALL patients were admitted between
May 2013 and December 2014 to the Hematology-Oncology
Unit, Durango State Cancer Center (Centro Estatal de
Cancerología, CECAN), Durango, Mexico. The ALL diagnosis
was based on the Franco-American British Association criteria
(Lilleyman et al., 1986). One hundred and thirty-three children
without ALL were used as the control group.
Genotyping
DNA extraction was performed using total blood samples
obtained by venous punctures using a commercial kit (Macherey-
Nagel R©, Düren, Germany). After extraction, DNA integrity and
purity were evaluated by horizontal electrophoresis in a 1%
agarose gel stained with ethidium bromide. The concentration
and quality were analyzed in a NanoDrop 2000 R© (Thermo
Scientific, Wilmington, DE, USA). Determination of single
nucleotide polymorphisms (SNPs) was analyzed using real-time
polymerase chain reaction (qPCR) by 48-well plate StepOne R©
Real-Time PCR system (Applied Biosystems, Carlsbad, CA,
USA) with TaqMan probes by Applied Biosystems StepOneTM
(Foster City, CA, USA). The SNPs COL181 (rs2274808),
SLC19A1 (rs2838956), ABCB1 (rs1045642, rs1128503), and
ABCC5 (rs9838667, rs3792585) were determined by a typical
reaction containing 5 ng/µl of DNA, 0.5µL of 20X TaqMan SNP
genotyping assay and 5.0µL of 2X TaqMan Genotyping Master
Mix (Foster City, CA, USA).
Statistical Analyses
Hardy-Weinberg equilibrium (HWE) and binding
disequilibrium analyses were conducted using expected
and observed genotypic and allelic frequencies in the study
population. The SNPStats (2006, Catalan Institute of Oncology,
Barcelona, Spain) software was used (Solé et al., 2006).
The relative risk associations of the COL18A1, ABCB1, and
ABCC5 genetic polymorphisms with ALL susceptibility were
assessed and were expressed as an odds ratio (OR) or a p <
0.05 with a 95% confidence interval (CI 95%). In addition,
analyses of the associations between binary combinations of
polymorphisms within the same locus and ALL were made
to establish the relationship with the pathology. Finally, we
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developed an artificial neural network architecture of three layers.
The first layer with covariates and factors, the second and hidden
layer was from 60 to 2 neurons, and the third layer was the
presence or absence of ALL (defined as the dependent variable).
SAS v9.0 (USA, 2002) and Statistica v7 (USA, 2004) softwares
were used. Fifty subjects were used for the training phase.
The best model was obtained by comparison through the 2log
Likelihood criteria and with the lower relative classification error.
RESULTS
Pediatric ALL patients and the controls showed a median
age of 7.92 and 5.85 years, respectively. The anthropometric
characteristics and biological parameters are presented in
Table 1. As expected, a difference in the pathognomonic variables
was observed between the groups.
Table 2 shows the allelic and genotypic frequencies for the
study groups and HWE values for the control group. The results
indicated five evaluated SNPs were in HWE, except ABCB1
(rs1128503). In addition, we determined significant differences
in allelic frequencies between SNPs.
To analyze the binary association responses, five inheritance
models were estimated (codominant, dominant, over-dominant,
recessive, and log-additive; Solé et al., 2006; Table 3). The best
model estimation was determined as a function of lower values
using the Akaike Information Criterion (AIC) and Bayesian
Information Criterion (BIC) compared to a reference model
(codominant: XX, wild type; XY, heterozygous; YY, homozygous)
Finally, the association with risk for ALL was estimated.
The associations among polymorphisms and ALL were
determined by the OR test (CI 95%, p < 0.05). The results
shown in Table 3 emphasize that the CT carriers for COL18A1
rs2274808 have a significant risk for ALL (OR = 2.55; CI95%,
1.11–5.83). This result was also found in the dominant model
CT-TT in relation to the wild type genotype. For SLC19A1
rs2838956, the best model was an over-dominant strategy where
AG subjects showed an atypical association with values of OR =
44.69.
Moreover, ABCB1 rs1045642 increased the ALL risk for
subjects carrying the TT genotype in both the codominant and
recessive models. The ABCB1 rs1128503 did not result in a risk
association to ALL.
The AC genotype for ABCC5 rs9838667 SNP was associated
with ALL susceptibility (OR= 2.61, CI 95% 1.05–6.48). However,
the ABCC5 rs3792585 SNP showed an increased risk for ALL in
subjects carrying the CC genotype, which was the same result
found in the recessive model.
Table 4 shows significant paired combinations for the closest
SNPs in each gene and their association with ALL susceptibility.
The results indicated that the COL18A1 (rs2274808)+SLC19A1
(rs2838956) combination, in relation to the wild type genotype
(CC+AA), had a significant association to ALL among
the CC+AG, CT+AG, TT+AG, and TT+GG combinations.
The combination of ABCB1 SNPs (rs1045642+rs1128503),
particularly the combinations of TT+CT and TT+TT, presented
a significant association to ALL. Finally, the total homozygote
combination of CC+CC showed an increased risk association
with ALL (OR: 5.33, CI 95% 2.59–1097). In contrast, the
AC+TT and AC+TC combinations were shown to be protective
against ALL.
The artificial neural network analysis determined that the
best general model was that of one layer with 48 hidden
TABLE 1 | Anthropometric characteristics and biochemical parameters of subjects.
Variable Case N = 73 (median, range) Control N = 133 (median, range) p-value*
Age(years) 7.92 (1.15–18.08) 5.85 (1.43–16.13) 0.022
Gender (male/female) 40 (54.79)/33 (45.21) 62 (47%)/71 (53%) 0.612
Body Weight (Kg) 17.5 (11.4–55.1) 22.9 (15.3–53.7) 0.120
Height (m) 1.07 (0.65–1.71) 1.22 (0.67–1.63) 0.216
Body surface (m2) 0.67 (0.43–1.7) 0.77 (0.57–1.34) 0.450
BMI (Kg/m2) 16.65 (12.36–28.1) 21 (18.5–27.5) 0.030
Time of treatment (weeks) 76 (25–289) – –
Dose MTX (low-high) 40.1 mg/m2–5 g/m2 – –
Hemoglobin (g/dL) 11.97 (7.00–16.8) 12.55 (11.06–14.3) 0.876
Hematocrit (%) 35.45 (27.2–47.0) 36.6 (34.6–45.1) 0.667
Erythrocyte (cell/mm3 ) 4.15 (2.85–5.89) × 106 4.3 (4.0–6.54) × 106 0.890
Leukocyte (cell/mm3 ) 3.61 (1.079–17.6) × 103 7.06 (5.9–14.2) × 103 0.011
Platelet (cell/mm3 ) 185.2 (22.2–378) × 103 255 (241–790) × 103 0.003
AST (UI/L) 36.85 (0.4–149) 14.0 (9.2–39.5) 0.010
ALT (UI/L) 46.6 (2.3–210) 19.4 (1.9–69) 0.006
Uric Acid (mg/dL) 3.42 (2.05–4.77) 3.77 (3.1–4.86) 0.758
Urea(mg/dL) 11.49 (8.89–61.75) 34.2 (10.7–63.2) 0.035
Creatinine (mg/dL) 0.70 (0.24–1.54) 0.8 (0.42–1.32) 0.870
Alkaline phosphatase (UI/L) 257 (46–359) 62 (42–335) 0.001
*p < 0.05.
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TABLE 2 | Allele and genotype frequencies of COL18A1, SLC19A1, ABCB1, ABCC5 polymorphisms in subjects.
Gene SNP Genotype Allele
Case Control HWE Case Control χ2
n (%) n (%) p-value* n (%) n (%)
COL18A1 rs2274808 CC 39 (0.53) 107 (0.80) 0.205 C 93 (0.64) 237 (0.89) 36.57*
CT 15 (0.21) 23 (0.17) T 53 (0.36) 29 (0.11)
TT 19 (0.16) 6 (0.02)
SLC19A1 rs2838956 AA 0 (0.00) 48 (0.36) 0.42 A 75 (0.51) 156 (0.59) 1.74
AG 71 (0.97) 60 (0.45) G 71 (0.49) 110 (0.41)
GG 2 (0.03) 25 (0.19)
ABCB1 rs1045642 CC 35 (0.48) 70 (0.53) 0.541 C 93 (0.64) 191 (0.72) 2.53
CT 23 (0.32) 51 (0.38) T 53 (0.36) 75 (0.28)
TT 15 (0.21) 12 (0.09)
rs1128503 CC 35 (0.48) 76 (0.57) 0.09 C 99 (0.68) 196 (0.74) 1.32
CT 29 (0.40) 44 (0.33) T 47 (0.32) 70 (0.26)
TT 9 (0.12) 13 (0.10)
ABCC5 rs9838667 AA 47 (0.64) 88 (0.66) 0.139 A 109 (0.75) 213 (0.80) 1.36
AC 15 (0.21) 37 (0.28) C 37 (0.25) 53 (0.20)
CC 11 (0.15) 8 (0.06)
rs3792585 TT 18 (0.25) 93 (0.70) 0.541 T 145 (0.74) 222 (0.83) 6.21*
TC 20 (0.27) 36 (0.27) C 51 (0.26) 44 (0.17)
CC 35 (0.48) 4 (0.03)
*p < 0.05.
neurons, an error-assay of 11.7% and an error-training of
14.8%, respectively. The results indicated the most important
normalized variables and pondered percentages for a response
to ALL were ABCB1 rs1045642 (72.8%), COL18A1 rs2274808
(56.7%), and ABCC5 rs3792585 (40.9%), resulting in the
following regression expression:
ALL susceptibility = 4.201− 0.921∗ rs2274808− 1.647
∗ rs1045642− 1.066 ∗ABCC5 rs3792585.
DISCUSSION
Pharmacokinetics, that is, absorption, distribution, metabolism,
and excretion (ADME) describe the disposition of a xenobiotic
within an organism. The four processes all influence the drug
exposure to the tissues and hence, influences efficacy and
safety of a compound/drug. In this sense, as in many other
compounds, ADME process for folates requires membrane
transporters (e.g., RFC1, ABC; Lage, 2008; Wolking et al., 2015).
Due to its role on nucleotide metabolism and DNA synthesis,
polymorphisms in genes associated to folate pathways may have
influence in cancer susceptibility and chemotherapeutic response
to methotrexate, an antifolate-antineoplastic drug (Ross and
Doyle, 2004; Steinberg et al., 2007; Galbiatti et al., 2013). It has
been shown that SNPs in folate-associated pathways give rise
to different phenotypes with direct clinical implicances and/or
pathological specific reactions (O’leary et al., 2006).
In order to evaluate this, in this study we analyzed six
polymorphisms in genes RFC1 and ABC’s and also COL18A1
(influencing the activity of these transporters), in relation to the
risk of occurrence of ALL.
Our results suggest that COL18A1 rs2274808 could represent
a risk factor for ALL. In addition, the dominant model, which
groups these 2 subpopulations, suggests a similar behavior. The
activity of COL18A1 rs2274808 was further validated by a study
which determined that a defect in COL18A1 would change
endostatin synthesis in a Salvadorian population (Mahajan
et al., 2010), consequently leading to an antiangiogenic disorder,
such as Knoblock syndrome and ALL; however, some authors
have indicated that children with ALL have variable levels of
endostatin (Dagdas et al., 2011), which makes it difficult to
accurately explain its relationship with the disease (Schneider
et al., 2007).
SLC19A1 rs2838956 was associated with the occurrence of
ALL (dominant model AG), which is similar to the results
reported by De Jonge et al. (2009) who found that a 80 G>A SNP
was significantly associated with ALL for both the heterozygote
and homozygote genotypes (Table 3). In contrast to our findings,
Yeoh et al. (2010) found in their case-control study of Malaysian
and Chinese populations (321 and 346 individuals, respectively)
that ALL children carrying the G>A genotype had protection
against the disease. However, the analysis of binary combinations
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TABLE 3 | Individual risk analyses for SNPs in relation to ALL.
Gene (SNP) Model Genotype Case n (%) Control n (%) OR 95%CI p-value* AIC BIC
COL18A1 (rs2274808)
Codominant CC 39 (53.4%) 107 (80.5%) 1.00 Reference 0.0001 240.0 260.0
CT 15 (20.6%) 23 (17.3%) 2.55 (1.11–5.83)
TT 19 (26%) 3 (2.3%) 21.05 (5.62–78.87)
Dominant CC 39 (53.4%) 107 (80.5%) 1.00 Reference <0.0001 248.6 265.2
CT-TT 34 (46.6%) 26 (19.6%) 5.01 (2.48–10.13)
SLC19A1 (rs2838956)
Codominant AA 0 (0%) 48 (36.1%) 1.00 Reference <0.0001 200.5 220.5
AG 71 (97.3%) 60 (45.1%) 0.00 NA
GG 2 (2.7%) 25 (18.8%) 0.00 NA
Overdominant AA-GG 2 (2.7%) 73 (54.9%) 1.00 Reference <0.0001 202.9 219.6
AG 71 (97.3%) 60 (45.1%) 44.69 (10.42–191.63)
ABCB1 (rs1045642)
Codominant CC 15 (20.6%) 70 (52.6%) 1.00 Reference <0.0001 223.6 243.6
CT 23 (31.5%) 51 (38.4%) 1.67 (0.77–3.63)
TT 35 (48%) 12 (9.0%) 17.43 (6.91–43.97)
Recessive CC-CT 38 (52%) 121 (91.0%) 1.00 Reference <0.0001 223.3 239.9
TT 35 (48%) 12 (9.0%) 13.76 (5.94–31.88)
ABCB1 (rs1128503)
Codominant CC 35 (48%) 76 (57.1%) 1.00 Reference 0.68 271.7 291.7
CT 29 (39.7%) 44 (33.1%) 1.33 (0.71–2.50)
TT 9 (12.3%) 13 (9.8%) 1.19 (0.45–3.15)
Overdominant CC-TT 44 (60.3%) 89 (66.9%) 1.00 Reference 0.13 236.0 248.5
CT 29 (39.7%) 44 (33.1%) 1.64 (0.86–3.16)
ABCC5 (rs9838667)
Codominant AA 47 (64%) 88 (66%) 1.00 Reference 0.41 235.8 251.4
AC 15 (21%) 37 (28%) 2.61 (1.05–6.48)
CC 11 (15%) 8 (6.0%) 1.10 (0.46–2.62)
Overdominant AA-CC 44 (60.3%) 96 (72%) 1.00 Reference 0.11 269.8 286.5
AC 29 (39.7%) 37 (28%) 1.29 (0.70–2.35)
ABCC5 (rs3792585)
Codominant TT 35 (48%) 93 (69.9%) 1.00 Reference 0.003 250.9 270.8
TC 20 (27.4%) 36 (27.1%) 1.42 (0.72–2.81)
CC 18 (24.7%) 4 (3%) 11.2 (3.50–35.91)
Recessive TT-TC 55 (75.3%) 129 (97%) 1.00 Reference 0.004 249.9 266.5
CC 18 (24.7%) 4 (3%) 9.99 (3.19–31.28)
AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion.
*p < 0.05.
showed that 4 SNPs are associated with a higher tendency to
develop ALL, which is a new finding.
The scientific literature, as reported by Ma et al. (2015a,b)
in two meta-analysis indicate no clear association between this
polymorphism and risk to ALL. In our study, we found that the
rs1045642 ABCB1 SNP (known as 3435C > T) was associated
with a risk of ALL occurrence. This finding is in agreement
with the studies by Jamroziak et al. (2004) in Polish children
carrying the TT genotype and by Qian et al. (2012) in a pediatric
Chinese population at risk for leukemogenesis in CT-TT vs. CC
individuals. However, the study by Hua-Jie et al. showed no
associations with the disease in a Chinese population (Hua-Jie
et al., 2011). Moreover, the results of Drain et al. (2009) suggested
that individuals carrying the ABCB1 rs1045642 variation should
have a beneficial impact because the overall survival rate would
be extended. In our risk analysis for ABCB1 rs11288503, we
found no relationship between this SNP and ALL susceptibility,
which contrasts the report by Ma et al. (2015a). However, when
we performed the study on the combination of both SNPs
(ABCB1 rs1045642+rs1128503), we observed that the rare allele
Frontiers in Pharmacology | www.frontiersin.org 5 August 2016 | Volume 7 | Article 238
Zaruma-Torres et al. SNPs, Folate Transport and ALL
TABLE 4 | Combined risk analyses for SNPs in relation to ALL.
Combined SNPs Case Control OR 95%CI p-value*
COL18A1 (rs2274808)+SLC19A1(rs2838956)
CC+AA 39 155 1.00 – –
CC+AG 110 167 2.62 (1.71–4.01) <0.0001
CT+AG 86 83 4.12 (2.59–6.54) <0.0001
TT+AG 90 66 5.42 (3.38–8.70) <0.0001
TT+GG 21 31 2.69 (1.39–5.19) 0.003
ABCB1 (rs1045642+rs1128503)
CC+CC 70 146 1.00 – –
TT+CT 44 56 1.64 (1.01–2.66) 0.040
TT+TT 24 25 2.00 (1.06–3.75) 0.029
ABCC5 (rs9838667+rs3792585)
AA+TT 82 181 1.00 – –
AC+TT 50 181 0.61 (0.40–0.91) 0.017
AC+TC 35 124 0.62 (0.39–0.98) 0.041
CC+CC 29 12 5.33 (2.59–10.97) <0.0001
*Only significant genotype combinations are included (p < 0.05).
combinations (TT+CT and TT+TT) were associated with a
higher risk for ALL, which explains why children carrying such
alleles are more likely to acquire the disease than those who have
combinations with wild type genotypes. This result is similar to
the reported by Semsei et al. (2008).
The results for the analyzed SNPs of ABCC5 (rs9838667
and rs3792585) demonstrated that only rs3792585 showed
a significant association with ALL susceptibility for subjects
carrying the CC genotype (Table 2). However, when both SNPs
were combined only homozygote genotype combinations showed
an increased risk of leukemogenesis (Table 4). Finally, the
AC+TT and AC+A/T combinations of ABCC5 were observed as
protection factors for ALL (Table 4).
For the risk analyses we used inheritance models to determine
risk genotypes for ALL, which is based in the idea that the
rare allele modify the risk, therefore the codominant model,
used as reference, explains a different risk for each genotype
which are non-additive. In the dominant model the risk for
heterozygote genotype is similar to the homozygote for the rare
allele. Conversely, in the recessive model the wild type genotype
and heterozygote genotype have similar risk. On the other hand,
in the over-dominant model the wild type genotype and the
homozygote for rare allele have similar risk. Finally, In the
additive model the basic idea is that a copy of the allele produces
half of the risk of the two alleles (Iniesta et al., 2005; Zintzaras
and Lau, 2008). In this respect, we choose the most probable
model (besides the codominant) for each polymorphic variants
to study risk. In this sense, our results (Table 3) showed that for
COL18A1 (rs2274808) the best model was de codominant, for
SLC19A1 (rs2838956) was the over-dominant model, for ABCB1
(rs1045642) was the codominant, non significantly different
to risk obtained from the recessive model, for the ABCB1
(rs1128503) and ABCC5 (rs9838667) there were not significant
associations for both the codominant or over-dominant models.
Finally for the ABCC5 (rs3792585) both the codominant and
recessive models gave a significant risk to ALL.
One limitation of this study was the modest sample size of the
cases (73). However, in our country, studies using children are
quite restricted, even more whether they are patients. Moreover,
considering there is an obligation to get both an informed
consent and an informed assent, we believe this is a good starting
number of subjects. In relation to that, there are several recent
published studies with relatively small number of children (Roy
Moulik et al., 2015; Amitai et al., 2016) and even more, with
adults with ALL (Hareedy et al., 2015). Despite this, we truly
believe our results are only a preliminary contribution regarding
the ALL susceptibility of our Mexican pediatric population.
In summary, we found that 4 SNPs (COL18A1 rs2274808,
SLC19A1 rs2838956, ABCB1 rs1045642, and ABCC5 rs3792585)
either alone, or in some combinations, were associated with a
higher risk for ALL in Mexican children. In contrast, children
carrying the AC+TT or AC+TC combined genotypes of ABCC5
seemed to be protected against ALL. These results suggest that
the inter-individual variability of each patient in genes associated
with the folate transport pathway influences the development
of ALL.
AUTHOR CONTRIBUTIONS
FZ, Analysis, interpretation of data, design and drafting the work,
final approval of the version to be published. IL, conception
and design of the work, interpretation of data, critical review
of the content, financial support, final approval of the version
to be published. VL, Interpretation of data, critical review of
the content, final approval of the version to be published.
AL, Interpretation of data, critical review of the content, final
approval of the version to be published. AR, Interpretation
of data, critical review of the content, final approval of the
version to be published.MS, Interpretation of data, critical review
of the content, final approval of the version to be published.
CG, Interpretation of data, critical review of the content, final
approval of the version to be published. MA, Interpretation of
data, critical review of the content, final approval of the version
to be published. MR, Interpretation of data, critical review of
the content, final approval of the version to be published. LQ,
Design of the work, interpretation of data, critical review of the
content, financial support, final approval of the version to be
published.
FUNDING
This work was partly financed with Chilean Fondecyt Grant
no. 1140434 and the National Polytechnic Institute-CIIDIR,
Durango, Mexico.
ACKNOWLEDGMENTS
The authors want to acknowledge the following people for
their assistance in this research: Lic. Cristina Venzor, principal
of CECAN- Nurse Service Unit, Durango-Mexico; Lic. Pedro
Cruz, General Director of Oncologic Pediatric Center of Baja
California, Mexico; Dr. Jesús Manuel Lozano, Medical Director
of Oncologic Pediatric Center of Baja California, Mexico; and
Carolyn Di Pietro-Arias for writing support.
Frontiers in Pharmacology | www.frontiersin.org 6 August 2016 | Volume 7 | Article 238
Zaruma-Torres et al. SNPs, Folate Transport and ALL
REFERENCES
Amitai, M., Kronenberg, S., Carmel, M., Michaelovsky, E., Frisch, A., Brent, D.,
et al. (2016). Pharmacogenetics of citalopram-related side effects in children
with depression and/or anxiety disorders. J. Neural. Transm. (Vienna). doi:
10.1007/s00702-016-1585-7. [Epub ahead of print].
Brisson, G. D., Alves, L. R., and Pombo-De-Oliveira, M. S. (2015). Genetic
susceptibility in childhood acute leukaemias: a systematic review.
Ecancermedicalscience 9, 1–28. doi: 10.3332/ecancer.2015.539
Choi, C. H. (2005). ABC transporters as multidrug resistance mechanisms and the
development of chemosensitizers for their reversal. Cancer Cell Int. 5:30. doi:
10.1186/1475-2867-5-30
Dagdas, S., Ozet, G., Yilmaz, M., Albayrak, M., and Ceran, F. (2011). Assessment of
plasma endostatin levels in patients with acute myeloblastic and lymphoblastic
leukemia. Int. J. Hematol. Oncol. 21, 210–216. doi: 10.4999/uhod.10015
De Jonge, R., Tissing, W. J., Hooijberg, J. H., Jansen, G., Kaspers, G. J., Lindemans,
J., et al. (2009). Polymorphisms in folate-related genes and risk of pediatric
acute lymphoblastic leukemia. Blood 113, 2284–2289. doi: 10.1182/blood-2008-
07-165928
Digtyar, A., Pozdnyakova, N., Feldman, N., Lutsenko, S., and Severin, S. (2007).
Endostatin: current concepts about its biological role and mechanisms of
action. Biochemistry 72, 235–246. doi: 10.1134/S0006297907030017
Drain, S., Catherwood, M. A., Orr, N., Galligan, L., Rea, I. M., Hodkinson,
C., et al. (2009). ABCB1 (MDR1) rs1045642 is associated with increased
overall survival in plasma cell myeloma. Leuk. Lymphoma 50, 566–570. doi:
10.1080/10428190902853144
Galbiatti, A. L., Castro, R., Caldas, H. C., Padovani, J. A. Jr., Pavarino, E. C., and
Goloni-Bertollo, E. M. (2013). Alterations in the expression pattern of MTHFR,
DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells
with high and low doses of methotrexate. Tumour Biol. 34, 3765–3771. doi:
10.1007/s13277-013-0960-3
Ganapathy, V., Smith, S. B., and Prasad, P. D. (2004). SLC19: the folate/thiamine
transporter family. Pflugers Arch. 447, 641–646. doi: 10.1007/s00424-003-1
068-1
Gottesman, M. M., Fojo, T., and Bates, S. E. (2002). Multidrug resistance in
cancer: role of ATP–dependent transporters. Nat. Rev. Cancer 2, 48–58. doi:
10.1038/nrc706
Hareedy, M. S., El Desoky, E. S., Woillard, J. B., Thabet, R. H., Ali, A. M., Marquet,
P., et al. (2015). Genetic variants in 6-mercaptopurine pathway as potential
factors of hematological toxicity in acute lymphoblastic leukemia patients.
Pharmacogenomics 16, 1119–1134. doi: 10.2217/PGS.15.62
Higgins, C. F. (2001). ABC transporters: physiology, structure andmechanism – an
overview. Res. Microbiol. 152, 205–210. doi: 10.1016/S0923-2508(01)01193-7
Holland, K. A., and Holland, I. B. (2005). Adventures with ABC-proteins: highly
conserved ATP-dependent transporters. Acta Microbiol. Inmunol. Hung. 52,
309–322. doi: 10.1556/AMicr.52.2005.3-4.4
Homberger, A., Linnebank, M.,Winter, C., Willenbring, H., Marquardt, T., Harms,
E., et al. (2000). Genomic structure and transcript variants of the human
methylenetetrahydrofolate reductase gene. Eur. J. Hum. Genet. 8, 725–729. doi:
10.1038/sj.ejhg.5200522
Hua-Jie, D., Kou-Rong, M., Chun, Q., Yun, Z., Wen-Yi, S., Ming, H., et al.
(2011). Polymorphisms and haplotypes in multidrug resistance 1 gene are not
associated with chronic lymphocytic leukemia susceptibility and prognostic
parameters of chronic lymphocytic leukemia in Chinese population. Leuk.
Lymphoma 52, 1003–1009. doi: 10.3109/10428194.2011.557454
Iniesta, R., Guinó, E., and Moreno, V. (2005). Statistical analysis of genetic
polymorphisms in epidemiological studies. Gac. Sanit. 19, 333–341. doi:
10.1157/13078029
Jamroziak, K., Młynarski, W., Balcerczak, E., Mistygacz, M., Trelin`ska, J.,
Mirowski, M., et al. (2004). Functional C3435T polymorphism of MDR1 gene:
an impact on genetic susceptibility and clinical outcome of childhood acute
lymphoblastic leukemia. Eur. J. Haematol. 72, 314–321. doi: 10.1111/j.1600-
0609.2004.00228.x
Jansen, G., and Pieters, R. (1998). The role of impaired transport in (pre) clinical
resistance to methotrexate: insights on new antifolates. Drug Resist. Updat. 1,
211–218. doi: 10.1016/S1368-7646(98)80042-3
Lage, H. (2008). An overview of cancer multidrug resistance: a still unsolved
problem. Cell Mol. Life Sci. 65, 3145–3167. doi: 10.1007/s00018-008-8111-5
Lilleyman, J. S., Hann, I. M., Stevens, R. F., Eden, O. B., and Richards, S.
M. (1986). French American British (FAB) morphological classification of
childhood lymphoblastic leukaemia and its clinical importance. J. Clin. Pathol.
39, 998–1002. doi: 10.1136/jcp.39.9.998
Ma, L., Liu, H., Ruan, L., Yang, X., Yang, H., and Feng, Y. (2015a). Multidrug
resistance gene 1 C1236T polymorphism and susceptibility to leukemia: a
meta-analysis. Biomed. Rep. 3, 83–87. doi: 10.3892/br.2014.387
Ma, L., Ruan, L., Liu, H., Yang, H., and Feng, Y. (2015b). ABCB1 C3435T
polymorphism is associated with leukemia susceptibility: evidence from a
meta-analysis. Onco Targets Ther. 8, 1009–1015. doi: 10.2147/OTT.S82144
Mahajan, V. B., Olney, A. H., Garrett, P., Chary, A., Dragan, E., Lerner,
G., et al. (2010). Collagen XVIII mutation in Knobloch syndrome with
acute lymphoblastic leukemia. Am. J. Med. Genet. A 152A, 2875–2879. doi:
10.1002/ajmg.a.33621
Moscow, J. A, Connolly, T., Myers, T. A, Cheng, C. A, Paull, K., and Cowan, K. H.
(1997). Reduced folate carrier (RFC1) expression and anti-folate resistance in
transfected and non-selected cell lines. Int. J. Cancer 72, 184–192.
O’leary, V. B., Pangilinan, F., Cox, C., Parle-McDermott, A., Conley, M., Molloy, A.
M., et al. (2006). Reduced folate carrier polymorphisms and neural tube defect
risk.Mol. Genet. Metab. 87, 364–369. doi: 10.1016/j.ymgme.2005.09.024
Pui, C.-H., Campana, D., Pei, D., Bowman, W. P., Sandlund, J. T., Kaste, S.
C., et al. (2009). Treating childhood acute lymphoblastic leukemia without
cranial irradiation. N. Engl. J. Med. 360, 2730–2741. doi: 10.1056/NEJMoa0
900386
Pui, C. H., Pei, D., Sandlund, J. T., Ribeiro, R. C., Rubnitz, J. E., Raimondi, S.
C., et al. (2010). Long-term results of St Jude Total Therapy Studies 11, 12,
13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 24,
371–382. doi: 10.1038/leu.2009.252
Qian, X., Cao, S., Yang, G., Dong, J., Jin, G., Shen, Y., et al. (2012).
Variant genotypes of MDR1 C3435T increase the risk of leukemia:
evidence from 10 case-control studies. Leuk. Lymphoma 53, 1183–1187. doi:
10.3109/10428194.2011.641179
Rodríguez, L., González-Llano, O.,Mancias, C., Pompa, T., González, G., Sandoval,
A., et al. (2010). Observaciones sobre la incidencia de leucemias agudas en el
Noreste de México. Rev. Hematol. Mex. 11, 78–81.
Ross, D. D., and Doyle, L. A. (2004). Mining our ABCs: pharmacogenomic
approach for evaluating transporter function in cancer drug resistance. Cancer
Cell 6, 105–107. doi: 10.1016/j.ccr.2004.08.003
Roy Moulik, N., Kumar, A., Agrawal, S., Awasthi, S., Mahdi, A. A., and Kumar,
A. (2015). Role of folate status and methylenetetrahydrofolate reductase
genotype on the toxicity and outcome of induction chemotherapy in children
with acute lymphoblastic leukemia. Leuk. Lymphoma 56, 1379–1384. doi:
10.3109/10428194.2014.947608
Schneider, P., Vasse, M., Corbiere, C., Legrand, E., Marie-Cardine, A., Boquet, C.,
et al. (2007). Endostatin variations in childhood acute lymphoblastic leukaemi–
comparison with basic fibroblast growth factor and vascular endothelial growth
factor. Leuk. Res. 31, 629–638. doi: 10.1016/j.leukres.2006.08.023
Semsei, Á. F., Erdélyi, D. J., Ungvári, I., Kámory, E., Csókay, B., Andrikovics, H.,
et al. (2008). Association of some rare haplotypes and genotype combinations
in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk. Res.
32, 1214–1220. doi: 10.1016/j.leukres.2007.12.009
Sertie, A., Sossi, V., Camargo, A., Zatz, M., Brahe, C., and Passos-Bueno,M. (2000).
Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor
growth, plays a critical role in the maintenance of retinal structure and in
neural tube closure (Knobloch syndrome).Hum.Mol. Genet. 9, 2051–2058. doi:
10.1093/hmg/9.13.2051
Sirotnak, F. M., and Tolner, B. (1999). Carrier-mediated membrane transport
of folates in mammalian cells. Annu. Rev. Nutr. 19, 91–122 doi: 10.1146/
annurev.nutr.19.1.91
Skibola, C. F., Smith, M. T., Kane, E., Roman, E., Rollinson, S., Cartwright, R. A.,
et al. (1999). Polymorphisms in the methylenetetrahydrofolate reductase gene
are associated with susceptibility to acute leukemia in adults. Proc. Natl. Acad.
Sci. U.S.A. 96, 12810–12815. doi: 10.1073/pnas.96.22.12810
Solé, X., Guinó, E., Valls, J., Iniesta, R., and Moreno, V. (2006). SNPStats: a web
tool for the analysis of association studies. Bioinformatics 22, 1928–1929. doi:
10.1093/bioinformatics/btl268
Steinberg, K. K., Relling, M. V., Gallagher, M. L., Greene, C. N., Rubin, C. S.,
French, D., et al. (2007). Genetic Studies of a cluster of acute lymphoblastic
Frontiers in Pharmacology | www.frontiersin.org 7 August 2016 | Volume 7 | Article 238
Zaruma-Torres et al. SNPs, Folate Transport and ALL
leukemia cases in churchill county, nevada. Environ. Health Perspect. 115,
158–164. doi: 10.1289/ehp.9025
Takatori, R., Takahashi, K. A., Tokunaga, D., Hojo, T., Fujioka, M., Asano, T., et al.
(2006). ABCB1 C3435T polymorphism influences methotrexate sensitivity in
rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24, 546–554.
Warren, M. S., Zerangue, N., Woodford, K., Roberts, L. M., Tate, E. H., Feng,
B., et al. (2009). Comparative gene expression profiles of ABC transporters in
brain microvessel endothelial cells and brain in five species including human.
Pharmacol. Res. 59, 404–413. doi: 10.1016/j.phrs.2009.02.007
Wielinga, P., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer,
N., et al. (2005). The human multidrug resistance protein MRP5 transports
folates and can mediate cellular resistance against antifolates. Cancer Res. 65,
4425–4430. doi: 10.1158/0008-5472.CAN-04-2810
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M., and Nies, A. T. (2015).
Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug
disposition and potential clinical implications: update of the literature. Clin.
Pharmacokinet. 54, 709–735. doi: 10.1007/s40262-015-0267-1
Yeoh, A. E. J., Lu, Y., Chan, J. Y. S., Chan, Y. H., Ariffin, H., Kham, S. K. Y., et al.
(2010). Genetic susceptibility to childhood acute lymphoblastic leukemia shows
protection in malay boys: results from the malaysia-singapore all study group.
Leuk. Res. 34, 276–283. doi: 10.1016/j.leukres.2009.07.003
Zeller, B., Gustafsson, G., Forestier, E., Abrahamsson, J., Clausen, N., Heldrup,
J., et al. (2005). Acute leukaemia in children with Down syndrome: a
population−based Nordic study. Br. J. Haematol. 128, 797–804. doi: 10.1111/
j.1365-2141.2005.05398.x
Zintzaras, E., and Lau, J. (2008). Synthesis of genetic association studies for
pertinent gene-disease associations requires appropriate methodological and
statistical approaches. J. Clin. Epidemiol. 61, 634–645. doi: 10.1016/j.jclinepi.
2007.12.011
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Zaruma-Torres, Lares-Asseff, Lima, Reyes-Espinoza,
Loera-Castañeda, Sosa-Macías, Galaviz-Hernández, Arias-Peláez, Reyes-López and
Quiñones. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 8 August 2016 | Volume 7 | Article 238
